Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from BioAge Labs, Inc. ( (BIOA) ) is now available.
On June 4, 2025, BioAge Labs, Inc. announced updates on the anticipated timing of key milestones in their NLRP3 and APJ Agonist programs. The company plans to submit an IND and initiate a Phase 1 SAD/MAD trial for the NLRP3 program by mid-2025, with initial data expected by the end of the year and full data by mid-2026. Additionally, proof-of-concept data for obesity is anticipated in the latter half of 2026. For the APJ Agonist program, BioAge Labs aims to submit an IND application by the end of 2026, reflecting their ongoing advancements in both oral and parenteral administration.
The most recent analyst rating on (BIOA) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on BioAge Labs, Inc. stock, see the BIOA Stock Forecast page.
Spark’s Take on BIOA Stock
According to Spark, TipRanks’ AI Analyst, BIOA is a Underperform.
BioAge Labs, Inc. is facing critical financial difficulties, characterized by no revenue generation, increasing losses, and dependence on external financing. The technical indicators suggest a bearish trend, and the lack of valuation metrics such as P/E ratio and dividend yield complicates valuation. These factors collectively reflect a weak overall stock performance.
To see Spark’s full report on BIOA stock, click here.
More about BioAge Labs, Inc.
Average Trading Volume: 249,080
Technical Sentiment Signal: Hold
Current Market Cap: $145.2M
See more data about BIOA stock on TipRanks’ Stock Analysis page.